Mallinckrodt (MNK) Q4 2024 earnings summary

Executive summary

• Mallinckrodt and Endo announced a merger to form a global-scale, diversified pharmaceutical leader with branded and generic businesses, targeting enhanced growth and value creation.

• The combined company expects 2025 pro forma revenue of $3.6 billion and adjusted EBITDA of $1.2 billion, with a 34% margin.

• The transaction is structured so Endo shareholders receive $80 million in cash and 49.9% of the combined company, with Mallinckrodt shareholders holding 50.1%.

• Achieved high end of full-year net sales guidance and midpoint of adjusted EBITDA guidance for 2024, with net sales up 6.1% to $2.0B and adjusted EBITDA up 5.6% to $603.7M year-over-year.

• The merger is expected to close in the second half of 2025, pending shareholder and regulatory approvals.

Financial highlights

• Endo reported 2024 revenues of $1.8 billion and adjusted EBITDA of $637 million, anchored by 9% growth in XIAFLEX revenues, which exceeded $500 million.

• Mallinckrodt reported 2024 net sales of $1.98 billion (up 6.1% year-over-year) and adjusted EBITDA of $603.7 million (up 5.6%).

• Full-year 2024 net income was $477.9M, a turnaround from a $1.67B net loss in 2023, largely due to the Therakos divestiture gain.

• Mallinckrodt's Q4 2024 net sales were $492.1 million, up 4.9% year-over-year; adjusted EBITDA was $124.2 million, flat year-over-year.

• Cash balance at year-end was $382.6M; total debt $865.6M; net debt $492.1M.

Outlook and guidance

• Endo's 2025 revenue guidance is $1.78–$1.86 billion, with adjusted EBITDA of $620–$650 million, reflecting low- to mid-single-digit growth.

• Mallinckrodt's 2025 guidance is for net sales of $1.7–$1.8 billion and adjusted EBITDA of $480–$520 million.

• Combined company expects at least $150 million in annual pre-tax run rate synergies by year three, with $75 million in the first year.

• Acthar Gel projected to grow in the low-single digits in 2025; Specialty Generics expected to deliver flat to low-single digit sales growth.

• Net leverage at closing is expected to be 2.3x.